Why PC-specific NAb are in vitro substantially more potent to block EC infection than NAb targeting other envelope glycoproteins is unclear, but this could be related to the mechanism of neutralization, antibody affinity, or the low amount of the PC incorporated into virions, which potentially requires only minor amounts of antibody to neutralize PC-dependent entry in vitro [57]. The gene discussed is ERVW-1; the disease is infection.